Tribendimidine

Tribendimidine is a broad-spectrum anthelmintic agent developed in China, at the National Institute of Parasitic Diseases in Shanghai. It is a derivative of amidantel.[1]

Tribendimidine
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC28H32N6
Molar mass452.594 g/mol g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

In clinical trials, it was highly effective in treating ankylostomiasis, ascariasis and enterobiasis.[2] However, animal studies suggest it is ineffective in treating Schistosoma mansoni or Fasciola hepatica disease.[1] The drug has also performed well in trials against opisthorchiasis, curing about 70% of cases.[3]

Tribendimidine is manufactured by Shandong Xinhua Pharmaceutical Company Limited in Zibo, Shandong, China. It was approved by the China Food and Drug Administration in 2007.

References

  1. Keiser J, Shu-Hua X, Chollet J, Tanner M, Utzinger J (2007). "Evaluation of the in vivo activity of tribendimidine against Schistosoma mansoni, Fasciola hepatica, Clonorchis sinensis, and Opisthorchis viverrini". Antimicrob Agents Chemother. 51 (3): 1096–8. doi:10.1128/AAC.01366-06. PMC 1803157. PMID 17194822. Free full text.
  2. Xiao SH, Hui-Ming W, Tanner M, Utzinger J, Chong W (2005). "Tribendimidine: a promising, safe and broad-spectrum anthelmintic agent from China". Acta Trop. 94 (1): 1–14. doi:10.1016/j.actatropica.2005.01.013. PMID 15777691.
  3. "New drug shows promise against Asian liver fluke". 2010-11-24.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.